Literature DB >> 17902024

Novel and recurrent ALDH3A2 mutations in Italian patients with Sjögren-Larsson syndrome.

Biagio Didona1, Andrea Codispoti2, Enrico Bertini3, Wiliam B Rizzo4, Gael Carney4, Giovanna Zambruno5, Carlo Dionisi-Vici3, Mauro Paradisi6, Cristina Pedicelli6, Gerry Melino7,8,9, Alessandro Terrinoni10.   

Abstract

Sjögren-Larsson syndrome (SLS; MIM#270200) is an autosomal recessive neurocutaneous disease caused by mutations in the ALDH3A2 gene for fatty aldehyde dehydrogenase (FALDH), a microsomal enzyme that catalyzes the oxidation of medium- and long- chain aliphatic aldehydes fatty acids. We studied two unrelated Italian SLS patients with ichthyosis, developmental delay, spastic diplegia and brain white matter disease. One patient was homozygous for a novel ALDH3A2 insertion mutation (c.767insA) in exon 5. The other SLS patient was a compound heterozygote for two previously reported mutations: a slice site mutation (c.1094C > T; S365L) in exon 7. Analysis of fibroblast RNA by RT-PCR indicated that the spice-site mutation caused skipping of exons 2 and 3. The c.1094C > T mutation, previously associated with two ALDH3A2 haplotypes, was found on a third distinct haplotype in our patient, which indicates that arose independently in this kindred. These results add to understanding of the genetic basis of SLS and will be useful for DNA diagnosis of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17902024      PMCID: PMC3057174          DOI: 10.1007/s10038-007-0180-z

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  7 in total

1.  Phenotypic and mutational spectrum of thirty-five patients with Sjögren-Larsson syndrome: identification of eleven novel ALDH3A2 mutations and founder effects.

Authors:  Mohamed S Abdel-Hamid; Mahmoud Y Issa; Hasnaa M Elbendary; Sherif F Abdel-Ghafar; Karima Rafaat; Heba Hosny; Marian Girgis; Ghada M H Abdel-Salam; Maha S Zaki
Journal:  J Hum Genet       Date:  2019-07-05       Impact factor: 3.172

2.  Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome.

Authors:  William B Rizzo
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-10       Impact factor: 0.694

3.  A gatekeeper helix determines the substrate specificity of Sjögren-Larsson Syndrome enzyme fatty aldehyde dehydrogenase.

Authors:  Markus A Keller; Ulrich Zander; Julian E Fuchs; Christoph Kreutz; Katrin Watschinger; Thomas Mueller; Georg Golderer; Klaus R Liedl; Markus Ralser; Bernhard Kräutler; Ernst R Werner; Jose A Marquez
Journal:  Nat Commun       Date:  2014-07-22       Impact factor: 14.919

4.  Genotype and phenotype variability in Sjögren-Larsson syndrome.

Authors:  Maximilian Weustenfeld; Reiner Eidelpes; Matthias Schmuth; William B Rizzo; Johannes Zschocke; Markus A Keller
Journal:  Hum Mutat       Date:  2018-11-26       Impact factor: 4.878

Review 5.  Sjogren-Larsson Syndrome: Mechanisms and Management.

Authors:  Parayil Sankaran Bindu
Journal:  Appl Clin Genet       Date:  2020-01-07

6.  Monitoring of fatty aldehyde dehydrogenase by formation of pyrenedecanoic acid from pyrenedecanal.

Authors:  Markus A Keller; Katrin Watschinger; Georg Golderer; Manuel Maglione; Bettina Sarg; Herbert H Lindner; Gabriele Werner-Felmayer; Alessandro Terrinoni; Ronald J A Wanders; Ernst R Werner
Journal:  J Lipid Res       Date:  2009-11-05       Impact factor: 5.922

7.  Sjogren-Larsson Syndrome: A case series of five members from an extended family with a novel mutation.

Authors:  Kamel T Abidi; Naglaa M Kamal; Ayman A Bakkar A; Maram Alotaibi; Haifa Asseri; Kawthar A Bokari
Journal:  Mol Genet Genomic Med       Date:  2020-09-15       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.